Radiology Department, Kasr Al-Aini Hospital, Faculty of Medicine, Cairo University, Cairo 11950, Egypt.
J Oncol. 2012;2012:292131. doi: 10.1155/2012/292131. Epub 2012 Feb 22.
Introduction. There has been limited information reported on the use of hepatic arterial therapy in liver dominant hepatic metastases arising from lung cancer. The aim of this study was to evaluate the safety and efficacy of hepatic arterial therapy in the treatment of liver dominant hepatic metastases arising from lung cancer. Methods. Thirteen patients underwent a total of 30 treatment sessions with Drug-Eluting Beads. Eight of the thirteen received only doxorubicin DEB (17 of the total treatments), and four patients received Irinotecan DEB (7 of the total treatments). Results. The planned preprocedural dosage was a median of 75 mg (range 19-200), with total hepatic dose exposure being a median of 150 mg (range 0-458), with a technical success rate of 97% in all 29 treatments. There were 4 adverse events related to treatment, but no evidence of hepatic insufficiency. Overall 6-month and 12-month response rates were 50%. After a median followup of 24 months, the median overall survival in this cohort was 14 months (range 7-48 months). Conclusion. Drug-eluting beads loaded with doxorubicin (DEBDOX) or irinotecan (DEBIRI) can be safely and effectively used in treatment of patients with liver predominant metastatic disease from lung cancer.
简介。关于肺癌肝转移所致肝优势型肝转移瘤应用肝动脉治疗的报道较少。本研究旨在评估载药微球（DEB）肝动脉化疗栓塞术（TACE）治疗肺癌肝转移所致肝优势型肝转移瘤的安全性和有效性。方法。13 例患者共进行了 30 次载药微球治疗，其中 8 例仅接受多柔比星 DEB（17 次治疗），4 例接受伊立替康 DEB（7 次治疗）。结果。计划的术前剂量中位数为 75mg（范围 19-200mg），总肝剂量中位数为 150mg（范围 0-458mg），29 次治疗中技术成功率为 97%。有 4 例与治疗相关的不良事件，但无肝失代偿证据。总的 6 个月和 12 个月的缓解率为 50%。中位随访 24 个月后，该队列的中位总生存期为 14 个月（范围 7-48 个月）。结论。载多柔比星 DEB（DEBDOX）或伊立替康 DEB（DEBIRI）可安全有效地用于治疗肺癌肝转移所致肝优势型肝转移瘤患者。
